Publications

Filters

Publications Atlas Journal Article Research Report

Clinical and Practice Brain diseases Cancer and cancer screening Cardiovascular disease Chronic diseases and multimorbidity Diet and nutrition Endocrinology Environmental health Eye, ear, nose and throat disorders Gastroenterology Hematology Infectious diseases Injuries and accidents Internal medicine Kidney disease Lung health Musculoskeletal diseases and disorders Organ transplantation and donation Pharmacoepidemiology and drug safety Reproductive medicine Skin diseases and disorders

Healthcare Providers and Services Acute and emergency services End-of-life care Home and community care Long-term care and continuing care Maternity and neonatal care Mental health and addictions Nursing Pediatrics Pharmacy Primary care Public health Rehabilitation Surgery

People and Society Children and young people Health and healthcare inequality Indigenous Peoples Marginalized populations Older people Racialized communities Women or gender-based research

Research and Methods Data science Decision science Epidemiology Health economics Health services research Implementation science and knowledge translation Policy and program evaluation Statistics Trials

From

ICES Central ICES McMaster ICES North ICES Queen's ICES UofT ICES uOttawa ICES Western

Cancer Cardiovascular Chronic Disease & Pharmacotherapy Kidney, Dialysis & Transplantation Life Stage Mental Health & Addictions Populations & Public Health Primary Care & Health Systems

Showing 1-10 of 148

Journal Article

01/03/2022

Association between increased dispensing of opioid agonist therapy take-home doses and opioid overdose and treatment interruption and discontinuation

Gomes T, Campbell TJ, Kitchen SA, Garg R, Bozinoff N, Men S, Tadrous M, Munro C, Antoniou T, Werb D, Wyman J. JAMA. 2022; 327(9):846-55. Epub 2022 Mar 1.

Journal Article

01/03/2022

Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: a population-based time-series analysis

Kitchen SA, Campbell TJ, Men S, Bozinoff N, Tadrous M, Antoniou T, Wyman J, Werb D, Munro C, Gomes T. Int J Drug Policy. 2022; 103:103644. Epub 2022 Mar 1.

Journal Article

07/02/2022

Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario

Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, Fell DB, Austin PC, Schwartz KL, Sundaram ME, Calzavara A, Chen B, Tadrous M, Wilson K, Wilson SE, Kwong JC; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators. Nat Microbiol. 2022; 7(3):379-85. Epub 2022 Feb 7.

Journal Article

14/12/2021

The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis

Boone CG, Antoniou T, Juurlink DN, von den Baumen TR, Kitchen SA, Richards GC, Tadrous M, Gomes T. CMAJ Open. 2021; 9(4):E1181-6. Epub 2021 Dec 14.

Journal Article

23/11/2021

Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis

Gomes T, McCormack D, Kitchen SA, Paterson JM, Mamdani MM, Proulx L, Bayliss L, Tadrous M. CMAJ Open. 2021; 9(4):E1055-62. Epub 2021 Nov 23.

Journal Article

23/11/2021

Comparison of claims from high-drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis

Tadrous M, Daniels B, Pearson S, Gomes T. CMAJ Open. 2021; 9(4):E1048-54. Epub 2021 Nov 23.

Journal Article

12/11/2021

Validation of self-reported opioid agonist treatment among people who inject drugs using prescription dispensation records

Bouck Z, Tricco AC, Rosella LC, Ling V, Gomes T, Tadrous M, Fox MP, Scheim AI, Werb D. Epidemiology. 2022; 33(2):287-94. Epub 2021 Nov 12.

Journal Article

25/10/2021

Assessment of stimulant use and cardiovascular event risks among older adults

Tadrous M, Shakeri A, Chu C, Watt J, Mamdani MM, Juurlink DN, Gomes T. JAMA Netw Open. 2021; 4(10):e2130795. Epub 2021 Oct 25.

Journal Article

20/08/2021

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study

Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, Chen B, Calzavara A, Fell DB, Austin PC, Wilson K, Schwartz KL, Brown KA, Gubbay JB, Basta NE, Mahmud SM, Righolt CH, Svenson LW, MacDonald SE, Janjua NZ, Tadrous M, Kwong JC; on behalf of the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators. BMJ. 2021; 374:n1943. Epub 2021 Aug 20.

Journal Article

06/08/2021

Greater than the sum: applying daily-dose equivalents to antipsychotic prescription claims to study real-world effects

Hayes KN, Gomes T, Tadrous M. Front Pharmacol. 2021; 12:709349. Epub 2021 Aug 6.

« Previous 1 … 7 8 9 10 11 … 15 Next »

Publications

Filters

Resource Type

Topic

Date

ICES Scientists

ICES Site

Research Program

Association between increased dispensing of opioid agonist therapy take-home doses and opioid overdose and treatment interruption and discontinuation

Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: a population-based time-series analysis

Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario

The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis

Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis

Comparison of claims from high-drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis

Validation of self-reported opioid agonist treatment among people who inject drugs using prescription dispensation records

Assessment of stimulant use and cardiovascular event risks among older adults

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study

Greater than the sum: applying daily-dose equivalents to antipsychotic prescription claims to study real-world effects